# Terumo partners with Orchestra BioMed for Virtue SEB balloon

Terumo Corporation has secured exclusive global development and commercialization rights to the Virtue Sirolimus-Eluting Balloon by entering into a strategic partnership with Orchestra BioMed. Terumo will make a $30 million upfront payment and a $5 million equity commitment.

- Type: Partnership
- Announced: 2019-06-13
- Value: $35.0M
- Status: announced
- Products: Virtue Sirolimus-Eluting Balloon
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [Terumo](https://endata.com/companies/2811.md) (partner)
- [Orchestra BioMed](https://endata.com/companies/39987.md) (partner)

## Sources

- [terumois.com](https://www.terumois.com/news/terumo-enhances-coronary-interventional-product-portfolio.html), 2019-06-13: "Terumo today announced that it has secured exclusive global development and commercialization rights to Virtue Sirolimus-Eluting Balloon for percutaneous coronary interventions."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.